<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29783268</article-id><article-id pub-id-type="pmc">5989624</article-id><article-id pub-id-type="doi">10.12659/MSM.906602</article-id><article-id pub-id-type="publisher-id">906602</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Lipidomic Components Alterations of Human Follicular Fluid Reveal the Relevance of Improving Clinical Outcomes in Women Using Progestin-Primed Ovarian Stimulation Compared to Short-Term Protocol</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Xiaowei</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="aff" rid="af2-medscimonit-24-3357">2</xref><xref ref-type="author-notes" rid="fn1-medscimonit-24-3357">A</xref><xref ref-type="author-notes" rid="fn2-medscimonit-24-3357">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-24-3357">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-24-3357">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-24-3357">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-24-3357">F</xref></contrib><contrib contrib-type="author"><name><surname>Kuang</surname><given-names>Yanping</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn7-medscimonit-24-3357">G</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Lixia</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="aff" rid="af2-medscimonit-24-3357">2</xref><xref ref-type="author-notes" rid="fn2-medscimonit-24-3357">B</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Baofeng</given-names></name><xref ref-type="aff" rid="af2-medscimonit-24-3357">2</xref><xref ref-type="author-notes" rid="fn4-medscimonit-24-3357">D</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qiuju</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn3-medscimonit-24-3357">C</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Yonglun</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn6-medscimonit-24-3357">F</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Zheng</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn2-medscimonit-24-3357">B</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Haiyan</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn4-medscimonit-24-3357">D</xref></contrib><contrib contrib-type="author"><name><surname>Lyu</surname><given-names>Qifeng</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn4-medscimonit-24-3357">D</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xie</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="af2-medscimonit-24-3357">2</xref><xref ref-type="author-notes" rid="fn1-medscimonit-24-3357">A</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chai</surname><given-names>Weiran</given-names></name><xref ref-type="aff" rid="af1-medscimonit-24-3357">1</xref><xref ref-type="author-notes" rid="fn1-medscimonit-24-3357">A</xref><xref ref-type="author-notes" rid="fn4-medscimonit-24-3357">D</xref><xref ref-type="author-notes" rid="fn6-medscimonit-24-3357">F</xref></contrib></contrib-group><aff id="af1-medscimonit-24-3357">
<label>1</label>Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute, Shanghai, P.R. China</aff><aff id="af2-medscimonit-24-3357">
<label>2</label>Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, P.R. China</aff><author-notes><corresp id="c1-medscimonit-24-3357">Corresponding Authors: Weiran Chai, e-mail: <email>chaiwrsh@126.com</email>; Jun Xie, e-mail: <email>Xiejun1968@126.com</email></corresp><fn id="fn1-medscimonit-24-3357"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-24-3357"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-24-3357"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-24-3357"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-24-3357"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-24-3357"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-24-3357"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>21</day><month>5</month><year>2018</year></pub-date><volume>24</volume><fpage>3357</fpage><lpage>3365</lpage><history><date date-type="received"><day>10</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>04</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>© Med Sci Monit, 2018</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>)</license-p></license></permissions><abstract><sec><title><offsets xml_i="6660" xml_f="6670" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="6681" xml_f="6712" txt_i="22" txt_f="53">Increasing the success rate of </offsets><italic><offsets xml_i="6720" xml_f="6728" txt_i="53" txt_f="61">in vitro</offsets></italic><offsets xml_i="6737" xml_f="7234" txt_i="61" txt_f="558"> fertilization/intracytoplasmic sperm injection (IVF/ICSI) is a duty of clinicians that has made many seek a variety of protocols. This study was undertaken to use a liquid chromatography-mass spectrometry (LC-MS) to define the alterations of follicular fluid (FF) lipid metabolites in patients undergoing progestin-primed ovarian stimulation (PPOS) compared with short-term protocol, revealing potential correlations between the differentially expressed lipids and ameliorative clinical outcomes.</offsets></p></sec><sec><title><offsets xml_i="7256" xml_f="7272" txt_i="560" txt_f="576">Material/Methods</offsets></title><p><offsets xml_i="7283" xml_f="7353" txt_i="577" txt_f="647">Ninety-three infertile women undergoing IVF/ICSI treatment with PPOS (</offsets><italic><offsets xml_i="7361" xml_f="7362" txt_i="647" txt_f="648">n</offsets></italic><offsets xml_i="7371" xml_f="7402" txt_i="648" txt_f="679">=62) or a short-term protocol (</offsets><italic><offsets xml_i="7410" xml_f="7411" txt_i="679" txt_f="680">n</offsets></italic><offsets xml_i="7420" xml_f="7621" txt_i="680" txt_f="881">=31) were prospectively enrolled in a randomized controlled trial. FF samples were obtained from dominant follicles at the time of oocyte retrieval. Lipid metabolism profiles were analyzed using LC-MS.</offsets></p></sec><sec><title><offsets xml_i="7643" xml_f="7650" txt_i="883" txt_f="890">Results</offsets></title><p><offsets xml_i="7661" xml_f="7831" txt_i="891" txt_f="1061">Twelve lipids were found to be higher in patients treated with the PPOS protocol than in those receiving the short-term protocol, including triacylglycerols (TAG-34: 1+NH</offsets><sub><offsets xml_i="7836" xml_f="7837" txt_i="1061" txt_f="1062">4</offsets></sub><offsets xml_i="7843" xml_f="7857" txt_i="1062" txt_f="1076">, TAG-58: 0+NH</offsets><sub><offsets xml_i="7862" xml_f="7863" txt_i="1076" txt_f="1077">4</offsets></sub><offsets xml_i="7869" xml_f="7883" txt_i="1077" txt_f="1091">, TAG-64: 3+NH</offsets><sub><offsets xml_i="7888" xml_f="7889" txt_i="1091" txt_f="1092">4</offsets></sub><offsets xml_i="7895" xml_f="7913" txt_i="1092" txt_f="1110">, and TAG-64: 8+NH</offsets><sub><offsets xml_i="7918" xml_f="7919" txt_i="1110" txt_f="1111">4</offsets></sub><offsets xml_i="7925" xml_f="7955" txt_i="1111" txt_f="1141">), diacylglycerol DAG-38: 6+NH</offsets><sub><offsets xml_i="7960" xml_f="7961" txt_i="1141" txt_f="1142">4</offsets></sub><offsets xml_i="7967" xml_f="8176" txt_i="1142" txt_f="1351">, phosphatidylglycerols (PG-26: 0, PG-30: 2, and PG-40: 5), phosphatidylethanolamine PE-32: 2, lysophosphatidylethanolamine LPE-14: 1, lysophosphatidylinositol LPI-12: 0, and lysophosphatidylcholine LPC-16: 0.</offsets></p></sec><sec><title><offsets xml_i="8198" xml_f="8209" txt_i="1353" txt_f="1364">Conclusions</offsets></title><p><offsets xml_i="8220" xml_f="8412" txt_i="1365" txt_f="1557">Our data demonstrate that the PPOS protocol increases the levels of 12 lipids in FF, which reveals a strong association between the differentially elevated lipids and better IVF/ICSI outcomes.</offsets></p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Follicular Fluid</kwd><kwd>Lipid Metabolism</kwd><kwd>Oocytes</kwd><kwd>Progesterone</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="8620" xml_f="8630" txt_i="1566" txt_f="1576">Background</offsets></title><p><offsets xml_i="8641" xml_f="8853" txt_i="1577" txt_f="1789">Follicular growth involves a complex pattern of hormonal signals regulated by the hypothalamus-pituitary-ovarian axis (HPOA) and by autocrine/paracrine signaling between oocytes and their adjacent somatic cells [</offsets><xref rid="b1-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="8904" xml_f="8905" txt_i="1789" txt_f="1790">1</offsets></xref><offsets xml_i="8912" xml_f="9248" txt_i="1790" txt_f="2126">]. These processes have been utilized by assisted reproductive technology in the clinic for 30 years to help more infertile couples conceive. There are still many factors affecting the success rate of IVF/ICSI, especially premature LH surges, which lead to early ovulation, causing failure in up to 20% of patients undergoing IVF/ICSI [</offsets><xref rid="b2-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="9299" xml_f="9300" txt_i="2126" txt_f="2127">2</offsets></xref><offsets xml_i="9307" xml_f="9308" txt_i="2127" txt_f="2128">,</offsets><xref rid="b3-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="9359" xml_f="9360" txt_i="2128" txt_f="2129">3</offsets></xref><offsets xml_i="9367" xml_f="9573" txt_i="2129" txt_f="2335">]. Gonadotropin-releasing hormone (GnRH) agonists and antagonist have been used to reduce surface expression of the GnRH receptor in the pituitary or reduce GnRH sensitivity to prevent premature LH surges [</offsets><xref rid="b4-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="9624" xml_f="9625" txt_i="2335" txt_f="2336">4</offsets></xref><offsets xml_i="9632" xml_f="9767" txt_i="2336" txt_f="2471">]. However, such protocols have increased the incidence of ovarian hyperstimulation syndrome and these surges range from 0.34% to 38% [</offsets><xref rid="b5-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="9818" xml_f="9819" txt_i="2471" txt_f="2472">5</offsets></xref><offsets xml_i="9826" xml_f="9827" txt_i="2472" txt_f="2473">–</offsets><xref rid="b7-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="9878" xml_f="9879" txt_i="2473" txt_f="2474">7</offsets></xref><offsets xml_i="9886" xml_f="10046" txt_i="2474" txt_f="2634">]. PPOS, created by Dr. Kuang, using medroxyprogesterone 17-acetate (MPA) negative feedback on the HPOA to inhibit the synthesis and secretion of pituitary LH [</offsets><xref rid="b8-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="10097" xml_f="10098" txt_i="2634" txt_f="2635">8</offsets></xref><offsets xml_i="10105" xml_f="10106" txt_i="2635" txt_f="2636">–</offsets><xref rid="b11-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="10158" xml_f="10160" txt_i="2636" txt_f="2638">11</offsets></xref><offsets xml_i="10167" xml_f="10371" txt_i="2638" txt_f="2842">]. This protocol is not only suitable for patients with a normal ovarian response, but has also been effectively applied in aged patients and those with low ovarian response and polycystic ovary syndrome.</offsets></p><p><offsets xml_i="10378" xml_f="10557" txt_i="2843" txt_f="3022">The development of oocytes, fertilization, and early embryo cleavage are influenced by the composition of FF, which provides a microenvironment comprising a variety of nutrients [</offsets><xref rid="b12-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="10609" xml_f="10611" txt_i="3022" txt_f="3024">12</offsets></xref><offsets xml_i="10618" xml_f="10742" txt_i="3024" txt_f="3148">]. The importance of FF in maintaining follicle development and oocyte quality has been extensively reported and discussed [</offsets><xref rid="b13-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="10794" xml_f="10796" txt_i="3148" txt_f="3150">13</offsets></xref><offsets xml_i="10803" xml_f="11545" txt_i="3150" txt_f="3892">]. In particular, with the recent development in mass spectrometric technology, metabolomics has been transformed into a principal tool in biomedical research to decipher fine changes in FF metabolism in the potential of follicle and oocyte development. Nevertheless, there have been no studies published to date describing a detailed analysis of FF compositions following IVF/ICSI treatment with methods such as PPOS. As progesterone (P) is also involved in the regulation of metabolism at multiple levels, such as glucose and lipoprotein lipase activity, we hypothesized that a LC-MS analysis of lipid profiles from FF samples can identify the association between the alterations and the ameliorative clinical outcomes in the PPOS protocol.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="11596" xml_f="11616" txt_i="3894" txt_f="3914">Material and Methods</offsets></title><sec sec-type="subjects"><title><offsets xml_i="11656" xml_f="11664" txt_i="3915" txt_f="3923">Patients</offsets></title><p><offsets xml_i="11675" xml_f="12834" txt_i="3924" txt_f="5083">Ninety-three infertile women undergoing IVF/ICSI in the Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine were prospectively recruited between March 2015 and June 2016. The patients were randomly divided into 2 protocols: PPOS protocols (4 or 10 mg) and short-term protocol. The maximum age was 35 years old, basal follicle-stimulating hormone (FSH) levels were less than 10 IU/ml, antral follicles (AFC) were greater than or equal to 5, and all had a normal body mass index (BMI) and regular menstrual cycles (MC) (27–35 days). We excluded patients with infertility induced by male factor infertility or uterine or tubal factor infertility, or unexplained infertility. Women with polycystic ovary syndrome, premature ovarian failure, cancer, a history of no used embryo, and more than 3 degrees of endometriosis were also excluded. Women were recruited according to different protocols: 31 patients receiving the short-term protocol served as the control group; 62 women were enrolled in the PPOS protocols, including 28 women with PPOS (4 mg) and 34 with PPOS (10 mg), based on the dose of MPA, undergoing IVF/ICSI treatment.</offsets></p></sec><sec><title><offsets xml_i="12856" xml_f="12898" txt_i="5085" txt_f="5127">Ethics approval and consent to participate</offsets></title><p><offsets xml_i="12909" xml_f="13214" txt_i="5128" txt_f="5433">The study was approved by the Ethics Review Committee of the Ninth People’s Hospital of Shanghai and the Shanghai Jiaotong University Medical Center, China. Signed informed consent for use of FF was obtained from each patient after recommending conventional infertility treatment and the IVF/ICSI process.</offsets></p></sec><sec><title><offsets xml_i="13236" xml_f="13244" txt_i="5435" txt_f="5443">Protocol</offsets></title><p><offsets xml_i="13255" xml_f="13273" txt_i="5444" txt_f="5462">In PPOS protocol [</offsets><xref rid="b14-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="13325" xml_f="13327" txt_i="5462" txt_f="5464">14</offsets></xref><offsets xml_i="13334" xml_f="13923" txt_i="5464" txt_f="6053">], MPA (Xianju Pharma, Zhejiang, China) 4 mg or 10 mg per day was taken orally from the MC3, and 150–225 IU human menopausal gonadotropin (hMG, Lizhu Pharmaceutical Trading Co., Zhuhai, China) until the day of induced ovulation. Depending on follicle development, we adjusted the dose of hMG. When the primary follicle reached 18 mm, 0.1 mg triptorelin (Huilin, Germany) and 2000–5000 IU human chorionic gonadotropin (hCG, Lizhu Pharmaceutical Trading Co., Zhuhai, China) were administrated to trigger ovulation. Transvaginal ultrasound-guided oocyte retrieval was performed 32–36 h later.</offsets></p><p><offsets xml_i="13930" xml_f="13958" txt_i="6054" txt_f="6082">In the short-term protocol [</offsets><xref rid="b15-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="14010" xml_f="14012" txt_i="6082" txt_f="6084">15</offsets></xref><offsets xml_i="14019" xml_f="14599" txt_i="6084" txt_f="6664">], triptorelin (Lizhu, Shanghai, China) 100 μg per day was injected from the MC3 until the day of hCG administration. Beginning on the day after the injection of triptorelin, 150–225 IU hMG was injected per day. Follicle development was monitored by ultrasound and we adjusted the dose of hMG based on the number and size of developing follicles. When the primary follicle reached 18 mm, or LH and P increased significantly compared with the baseline, 2000–5000 IU hCG was injected to trigger ovulation. Transvaginal ultrasound-guided oocyte retrieval was performed 32–36 h later.</offsets></p></sec><sec><title><offsets xml_i="14621" xml_f="14651" txt_i="6666" txt_f="6696">Collection of follicular fluid</offsets></title><p><offsets xml_i="14662" xml_f="14984" txt_i="6697" txt_f="7019">For each patient, the first follicle was carefully collected to avoid macroscopic blood contamination and a new needle was used for each patient. Each 3–5 mL of FF aspirate was centrifuged immediately at 2000 g for 20 min at 4°C, then the extracted FF supernatant was aliquoted (1.5 mL) and stored at −80°C prior to assay.</offsets></p></sec><sec><title><offsets xml_i="15006" xml_f="15024" txt_i="7021" txt_f="7039">Sample preparation</offsets></title><p><offsets xml_i="15035" xml_f="15432" txt_i="7040" txt_f="7437">Using methyl tert-butyl ether, we extracted the lipid molecules of follicular fluid twice. The organic phase was volatilized by the vacuum centrifugal concentration meter and the evaporated sample was redissolved by the mixed solvent. We transferred the redissolved samples to the sample vials for high performance liquid chromatography-electrospray time-of-flight mass spectrometry (HPLC-TOF-MS).</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="15473" xml_f="15513" txt_i="7439" txt_f="7479">Metabolomic analysis of follicular fluid</offsets></title><p><offsets xml_i="15524" xml_f="16026" txt_i="7480" txt_f="7982">The lipid molecules of follicular fluid samples were analyzed by HPLC-TOF-MS, which used a charged surface hybrid C18 chromatographic column as the chromatography/mass spectrum, 2.1×100 mm, 1.7 μm, flow velocity was 0.4 mL/min, and column temperature was held at 55°C. Gradient elution was used to elute the analyte, and we added 1-μL samples into the column conducted under electrospray ionization positive and negative ion mode. TOF/MS/MS was set to MS scanning, and total scan time cycle was 0.83 s.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="16067" xml_f="16097" txt_i="7984" txt_f="8014">Metabolic correlation analysis</offsets></title><p><offsets xml_i="16108" xml_f="16341" txt_i="8015" txt_f="8248">Heat Map analyzed the metabolites and the similarity relation between samples to confirm which sample has a similar metabolic profile and metabolic path, and then gathered similar metabolites. The clustering software was R language (</offsets><italic><ext-link ext-link-type="uri" xlink:href="www.r-project.org"><offsets xml_i="16410" xml_f="16427" txt_i="8248" txt_f="8265">www.r-project.org</offsets></ext-link></italic><offsets xml_i="16447" xml_f="16695" txt_i="8265" txt_f="8513">) package Pheatmap. Correlation analysis was used for calculating coefficient of association among the metabolites, including each group of data matrix by Pearson’s product–moment correlation and p-value of correcting by false discovery rate (FDR).</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="16736" xml_f="16756" txt_i="8515" txt_f="8535">Statistical analysis</offsets></title><p><offsets xml_i="16767" xml_f="17766" txt_i="8536" txt_f="9535">SPSS22.0 software was used for statistical analysis. Statistical analysis of normally distributed data was performed on 2 independent samples. The Mann-Whitney U test was used to measure non-normally distributed data. The categorical data were analyzed by chi-square test. LipidView (AB Sciex,1.2) software was utilized for lipid analysis by accurate mass and MS/MS fragment. LipidView software was used for quantitative results by comparing the target lipid peak area and their internal standard. To utilize quality control sample data for quality assurance analysis, Simca-P 13.0 (Umetrics AB, Umea, Sweden) software was used for principal component analysis (PCA). Then, partial least squares-discriminant analysis (PLS-DA) was applied to the data set, and after the construction of the PLS-DA models, a permutation test was used to prevent overfitting. Orthogonal partial least square-discriminate analysis (OPLS-DA) was applied to explore differences between the 3 groups of lipids. A 2-sample </offsets><italic><offsets xml_i="17774" xml_f="17775" txt_i="9535" txt_f="9536">t</offsets></italic><offsets xml_i="17784" xml_f="17854" txt_i="9536" txt_f="9606"> test was used to assess differences between the 2 groups by R 3.3.0 (</offsets><italic><ext-link ext-link-type="uri" xlink:href="www.r-project.org"><offsets xml_i="17923" xml_f="17940" txt_i="9606" txt_f="9623">www.r-project.org</offsets></ext-link></italic><offsets xml_i="17960" xml_f="18054" txt_i="9623" txt_f="9711">), and P&lt;0.05 and fold change &gt;1.5 were regarded as indicating a significant difference.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="18101" xml_f="18108" txt_i="9714" txt_f="9721">Results</offsets></title><sec sec-type="intro|subjects"><title><offsets xml_i="18154" xml_f="18194" txt_i="9722" txt_f="9762">Clinical characteristics of the patients</offsets></title><p><offsets xml_i="18205" xml_f="18255" txt_i="9763" txt_f="9813">A total of 93 women were recruited for the study. </offsets><xref ref-type="table" rid="t1-medscimonit-24-3357"><offsets xml_i="18307" xml_f="18314" txt_i="9813" txt_f="9820">Table 1</offsets></xref><offsets xml_i="18321" xml_f="19078" txt_i="9820" txt_f="10577"> shows characteristics of the 62 patients who underwent 1 of 2 PPOS protocols (4 or 10 mg) and the 31 control participants in the short-term protocol that were finally selected for inclusion in the study. There were no significant differences among the 3 groups with respect to age, infertility time, cause of infertility, basal hormone level, antral follicle count, percentage of primary infertility, previous IVF attempts, or body mass index. Furthermore, there were no significant differences in total doses of human menopausal and chorionic gonadotropins, the numbers of oocytes retrieved, the numbers of fertilizations and embryos, or the rates of clinical pregnancy. However, significant differences were found among groups for the total doses of MPA.</offsets></p></sec><sec><title><offsets xml_i="19100" xml_f="19128" txt_i="10579" txt_f="10607">Serum hormone of each groups</offsets></title><p><offsets xml_i="19139" xml_f="19260" txt_i="10608" txt_f="10729">The levels of serum hormones detected during ovarian stimulation with the PPOS and short-term protocols are presented in </offsets><xref ref-type="fig" rid="f1-medscimonit-24-3357"><offsets xml_i="19310" xml_f="19318" txt_i="10729" txt_f="10737">Figure 1</offsets></xref><offsets xml_i="19325" xml_f="19854" txt_i="10737" txt_f="11266">. The levels of FSH in patients receiving ovarian stimulation with the PPOS protocol were higher than in those receiving the short-term protocol, appearing as a FSH surge on the trigger day. The levels of LH decreased in the PPOS protocol but increased and were maintained at a higher level in the short-term protocol. By contrast, the levels of estrogen (E2) and P were significantly lower with the PPOS protocol than with the short-term protocol. There were no significant differences between the 4-mg and 10-mg PPOS protocols.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="19895" xml_f="19965" txt_i="11268" txt_f="11338">Overall lipid analysis and pattern recognition and functional analysis</offsets></title><p><offsets xml_i="19976" xml_f="20486" txt_i="11339" txt_f="11849">A total of 294 lipids, including 276 positive ions and 18 negative ions, were obtained according to the quality assurance, and 12 lipid molecules were identified, including PA, PC, PE, PG, PI, PS, CE, TAGs, DAGs, Cer, SM, and free fatty acids. A PCA revealed that the metabolic profiles from FF samples differed among the 3 groups. Furthermore, an OPLS-DA model with good predictability was applied to compare the PPOS and short-term groups. These analyses revealed significant differences among the 3 groups (</offsets><xref ref-type="fig" rid="f2-medscimonit-24-3357"><offsets xml_i="20536" xml_f="20544" txt_i="11849" txt_f="11857">Figure 2</offsets></xref><offsets xml_i="20551" xml_f="20553" txt_i="11857" txt_f="11859">).</offsets></p></sec><sec><title><offsets xml_i="20575" xml_f="20626" txt_i="11861" txt_f="11912">Differences in metabolites with ovarian stimulation</offsets></title><p><offsets xml_i="20637" xml_f="20698" txt_i="11913" txt_f="11974">Based on the OPLS-DA model, together with the p-value of the </offsets><italic><offsets xml_i="20706" xml_f="20707" txt_i="11974" txt_f="11975">t</offsets></italic><offsets xml_i="20716" xml_f="20922" txt_i="11975" txt_f="12178"> test (p&lt;0.05) and a greater that 1.5-fold difference, significant augmentation in the levels of 12 lipids metabolites were observed in the PPOS groups compared with the short-term group. As detailed in </offsets><xref ref-type="fig" rid="f3-medscimonit-24-3357"><offsets xml_i="20972" xml_f="20980" txt_i="12178" txt_f="12186">Figure 3</offsets></xref><offsets xml_i="20987" xml_f="21041" txt_i="12186" txt_f="12240">, those lipids included triacylglycerols (TAG-34: 1+NH</offsets><sub><offsets xml_i="21046" xml_f="21047" txt_i="12240" txt_f="12241">4</offsets></sub><offsets xml_i="21053" xml_f="21067" txt_i="12241" txt_f="12255">, TAG-58: 0+NH</offsets><sub><offsets xml_i="21072" xml_f="21073" txt_i="12255" txt_f="12256">4</offsets></sub><offsets xml_i="21079" xml_f="21093" txt_i="12256" txt_f="12270">, TAG-64: 3+NH</offsets><sub><offsets xml_i="21098" xml_f="21099" txt_i="12270" txt_f="12271">4</offsets></sub><offsets xml_i="21105" xml_f="21123" txt_i="12271" txt_f="12289">, and TAG-64: 8+NH</offsets><sub><offsets xml_i="21128" xml_f="21129" txt_i="12289" txt_f="12290">4</offsets></sub><offsets xml_i="21135" xml_f="21165" txt_i="12290" txt_f="12320">), diacylglycerol DAG-38: 6+NH</offsets><sub><offsets xml_i="21170" xml_f="21171" txt_i="12320" txt_f="12321">4</offsets></sub><offsets xml_i="21177" xml_f="21386" txt_i="12321" txt_f="12530">, phosphatidylglycerols (PG-26: 0, PG-30: 2, and PG-40: 5), phosphatidylethanolamine PE-32: 2, lysophosphatidylethanolamine LPE-14: 1, lysophosphatidylinositol LPI-12: 0, and lysophosphatidylcholine LPC-16: 0.</offsets></p><p><offsets xml_i="21393" xml_f="21697" txt_i="12531" txt_f="12835">Two-way hierarchical clustering of these metabolites revealed small differences within groups, with good sample repeatability. Overall, patterns of lipid expression in the PPOS groups differed significantly from that of the short-term group, with most of the lipids showing upregulation with 10 mg PPOS (</offsets><xref ref-type="fig" rid="f4-medscimonit-24-3357"><offsets xml_i="21747" xml_f="21756" txt_i="12835" txt_f="12844">Figure 4A</offsets></xref><offsets xml_i="21763" xml_f="21965" txt_i="12844" txt_f="13046">). Correlational analyses showed that there was a correlation between the selected variables and a high correlation between TAG-34: 1+NH4, TAG 58: 0+NH4, TAG 64: 3+NH4, TAG 64: 8+NH4 and DAG 38: 6+NH4 (</offsets><xref ref-type="fig" rid="f4-medscimonit-24-3357"><offsets xml_i="22015" xml_f="22024" txt_i="13046" txt_f="13055">Figure 4B</offsets></xref><offsets xml_i="22031" xml_f="22033" txt_i="13055" txt_f="13057">).</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="22083" xml_f="22093" txt_i="13060" txt_f="13070">Discussion</offsets></title><p><offsets xml_i="22104" xml_f="22531" txt_i="13071" txt_f="13498">In this study, we performed LC-MS analysis of FF lipid composition from patients undergoing IVF/ICSI treatment with 4 or 10 mg PPOS or a short-term protocol. We identified 12 differentially expressed lipids that were associated with the dose of MPA in the PPOS treatment that achieved high-quality oocytes and satisfactory pregnancy outcomes. Future studies will reveal the mechanism(s) for the alteration in the lipid profile.</offsets></p><p><offsets xml_i="22538" xml_f="22794" txt_i="13499" txt_f="13755">The main characteristic of the PPOS protocol is the use of a high dose of MPA to reduce LH levels to produce more follicles during the follicular phase. Although a study found that P can inhibit follicular activity in llamas by suppressing LH pulsatility [</offsets><xref rid="b16-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="22846" xml_f="22848" txt_i="13755" txt_f="13757">16</offsets></xref><offsets xml_i="22855" xml_f="22946" txt_i="13757" txt_f="13848">], another study showed that P treatment correlates with the emergence of young follicles [</offsets><xref rid="b17-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="22998" xml_f="23000" txt_i="13848" txt_f="13850">17</offsets></xref><offsets xml_i="23007" xml_f="23177" txt_i="13850" txt_f="14020">]. Moreover, the cumulus complex secretes P to promote follicle maturation, and this high P environment had no effect on the process of follicular development in humans [</offsets><xref rid="b18-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="23229" xml_f="23231" txt_i="14020" txt_f="14022">18</offsets></xref><offsets xml_i="23238" xml_f="23471" txt_i="14022" txt_f="14255">]. Indeed, it is widely accepted that P can slow the frequency of LH secretion in the early stages of follicle development, effectively suppressing premature LH surges, but does not damage the follicular development at later stages [</offsets><xref rid="b19-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="23523" xml_f="23525" txt_i="14255" txt_f="14257">19</offsets></xref><offsets xml_i="23532" xml_f="23533" txt_i="14257" txt_f="14258">–</offsets><xref rid="b21-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="23585" xml_f="23587" txt_i="14258" txt_f="14260">21</offsets></xref><offsets xml_i="23594" xml_f="23925" txt_i="14260" txt_f="14591">]. Interestingly, PPOS also induced an increase in basal serum FSH by using hMG, which surged on the trigger day. Studies suggest that a surge in FSH before ovulation also promotes the development of the follicles, and the appearance of the FSH surge before ovulation effectively improves the developmental potential of follicles [</offsets><xref rid="b22-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="23977" xml_f="23979" txt_i="14591" txt_f="14593">22</offsets></xref><offsets xml_i="23986" xml_f="23987" txt_i="14593" txt_f="14594">–</offsets><xref rid="b24-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="24039" xml_f="24041" txt_i="14594" txt_f="14596">24</offsets></xref><offsets xml_i="24048" xml_f="24111" txt_i="14596" txt_f="14659">]. However, the underlying molecular mechanisms remain elusive.</offsets></p><p><offsets xml_i="24118" xml_f="24457" txt_i="14660" txt_f="14999">Our analyses revealed that PGs, including PG-26: 0, PG-30: 2, and PG-40: 5, were higher in FF from patients treated with the PPOS protocol. PG is a lipid mediator synthesized by arachidonic acid in the cyclooxygenase pathway, which plays important roles in LH secretion, follicular development, fertilization, and blastocyst implantation [</offsets><xref rid="b25-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="24509" xml_f="24511" txt_i="14999" txt_f="15001">25</offsets></xref><offsets xml_i="24518" xml_f="24519" txt_i="15001" txt_f="15002">,</offsets><xref rid="b26-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="24571" xml_f="24573" txt_i="15002" txt_f="15004">26</offsets></xref><offsets xml_i="24580" xml_f="24909" txt_i="15004" txt_f="15333">]. Also, PGs are involved in mammalian ovulation by stimulating the follicular wall smooth muscle contraction, leading to follicular rupture and ovulation, which are mediated by the cAMP signaling system. Furthermore, a reduction of PGs results in many spermatozoa that cannot penetrate cumulus cells when levels of PGs are low [</offsets><xref rid="b27-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="24961" xml_f="24963" txt_i="15333" txt_f="15335">27</offsets></xref><offsets xml_i="24970" xml_f="24971" txt_i="15335" txt_f="15336">–</offsets><xref rid="b29-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="25023" xml_f="25025" txt_i="15336" txt_f="15338">29</offsets></xref><offsets xml_i="25032" xml_f="25224" txt_i="15338" txt_f="15530">]. Thus, the finding from our study of higher PG levels with the PPOS protocol is consistent with these results. PGs receptors located in many tissue cell membranes play a different function [</offsets><xref rid="b30-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="25276" xml_f="25278" txt_i="15530" txt_f="15532">30</offsets></xref><offsets xml_i="25285" xml_f="25784" txt_i="15532" txt_f="16031">]. They mediate the physiological functions of PGs through their second messenger pathways, stimulating or inhibiting the activity of adenylatecyclopase (AC) in the cell membrane to increase or decrease the level of cAMP. This suggests that PGs not only promote the ovulation of mature follicles, but also act as a second messenger of GnRH-mediated granule cells on cAMP response to promote the proliferation of follicular granulosa cells by mediating the PKA signaling pathway of the FSH in cells [</offsets><xref rid="b31-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="25836" xml_f="25838" txt_i="16031" txt_f="16033">31</offsets></xref><offsets xml_i="25845" xml_f="25925" txt_i="16033" txt_f="16113">], which in turn plays an important role in the selection of dominant follicles.</offsets></p><p><offsets xml_i="25932" xml_f="26178" txt_i="16114" txt_f="16360">Another important finding of our study was that levels of TAGs and DAGs in FF samples were increased by PPOS. As second messengers, these metabolites play important roles in cell signal transduction, proliferation, differentiation, and survival [</offsets><xref rid="b32-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="26230" xml_f="26232" txt_i="16360" txt_f="16362">32</offsets></xref><offsets xml_i="26239" xml_f="26240" txt_i="16362" txt_f="16363">–</offsets><xref rid="b34-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="26292" xml_f="26294" txt_i="16363" txt_f="16365">34</offsets></xref><offsets xml_i="26301" xml_f="26519" txt_i="16365" txt_f="16583">]. However, little is known about the effects of high TAG levels on human oocyte development. Animal studies have shown that TAGs can be used as the key energy source in bovine oocyte maturation and embryo development </offsets><italic><offsets xml_i="26527" xml_f="26535" txt_i="16583" txt_f="16591">in vitro</offsets></italic><offsets xml_i="26544" xml_f="26546" txt_i="16591" txt_f="16593"> [</offsets><xref rid="b35-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="26598" xml_f="26600" txt_i="16593" txt_f="16595">35</offsets></xref><offsets xml_i="26607" xml_f="26712" txt_i="16595" txt_f="16700">]. TAGs account for 60% of the neutral lipids in oocytes and accumulate with oocyte growth in the insect </offsets><italic><offsets xml_i="26720" xml_f="26737" txt_i="16700" txt_f="16717">Rhodnius prolixus</offsets></italic><offsets xml_i="26746" xml_f="26748" txt_i="16717" txt_f="16719"> [</offsets><xref rid="b36-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="26800" xml_f="26802" txt_i="16719" txt_f="16721">36</offsets></xref><offsets xml_i="26809" xml_f="26981" txt_i="16721" txt_f="16893">]. Future studies evaluating the relationship between TAG levels and human oocyte development are needed. With regard to DAGs, a previous study has shown that P stimulates </offsets><italic><offsets xml_i="26989" xml_f="26993" txt_i="16893" txt_f="16897">Rana</offsets></italic><offsets xml_i="27002" xml_f="27048" txt_i="16897" txt_f="16943"> sp. oocytes to release large amounts of DAG [</offsets><xref rid="b37-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="27100" xml_f="27102" txt_i="16943" txt_f="16945">37</offsets></xref><offsets xml_i="27109" xml_f="27300" txt_i="16945" txt_f="17136">]. Consistent with this, we found the IVF/ICSI treatment that induces high levels of P increases DAGs. Eckberg and Szuts similarly found that DAGs initiate the meiotic maturation of oocytes [</offsets><xref rid="b38-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="27352" xml_f="27354" txt_i="17136" txt_f="17138">38</offsets></xref><offsets xml_i="27361" xml_f="27493" txt_i="17138" txt_f="17270">]. Furthermore, Albessard et al. found that levels of TAG, DAG, and PA were higher in ready-to-spawn ovaries than in spent females [</offsets><xref rid="b39-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="27545" xml_f="27547" txt_i="17270" txt_f="17272">39</offsets></xref><offsets xml_i="27554" xml_f="27697" txt_i="17272" txt_f="17415">]. These findings demonstrate the crucial relationship between TAG and DAG, and the developmental potential of oocytes in a high P environment.</offsets></p><p><offsets xml_i="27704" xml_f="27991" txt_i="17416" txt_f="17703">A remarkable finding of this study is the elevation of LPC and LPI. LPC can activate several second messengers, including extracellular-signal-regulated kinases and protein kinase C, which have been shown to be involved in the regulation of follicular development and oocyte maturation [</offsets><xref rid="b40-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="28043" xml_f="28045" txt_i="17703" txt_f="17705">40</offsets></xref><offsets xml_i="28052" xml_f="28053" txt_i="17705" txt_f="17706">–</offsets><xref rid="b42-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="28105" xml_f="28107" txt_i="17706" txt_f="17708">42</offsets></xref><offsets xml_i="28114" xml_f="28417" txt_i="17708" txt_f="18011">]. Likewise, LPI (specifically, LPI-12: 0), acts as a second messenger in the regulation of P and activates phosphoinositide 3-kinase signaling, which also modulates follicle development via the mammalian pre-implantation nutrition ligand, and is needed for cell survival and the first embryo division [</offsets><xref rid="b43-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="28469" xml_f="28471" txt_i="18011" txt_f="18013">43</offsets></xref><offsets xml_i="28478" xml_f="28479" txt_i="18013" txt_f="18014">,</offsets><xref rid="b44-medscimonit-24-3357" ref-type="bibr"><offsets xml_i="28531" xml_f="28533" txt_i="18014" txt_f="18016">44</offsets></xref><offsets xml_i="28540" xml_f="28716" txt_i="18016" txt_f="18192">]. Therefore, we propose that the P-induced elevation of LPC and LPI levels in FF of the PPOS protocol regulates follicular development by activating several second messengers.</offsets></p><p><offsets xml_i="28723" xml_f="28900" txt_i="18193" txt_f="18370">Our findings also showed that levels of PE and LPE were altered in FF by the PPOS protocol. However, further studies are needed to investigate the significance of these changes.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="28945" xml_f="28956" txt_i="18372" txt_f="18383">Conclusions</offsets></title><p><offsets xml_i="28967" xml_f="29297" txt_i="18384" txt_f="18714">In conclusion, the results of these analyses demonstrate that use of the PPOS protocol alters the lipid profiles in FF. Moreover, these changes reveal the strong relevance of the differentially elevated lipids and better IVF/ICSI outcomes. The mechanisms by which these changes influence IVF/ICSI outcomes remain to be elucidated.</offsets></p></sec></body><back><ack><title>Acknowledgements</title><p>We also thank researcher Xiaoling Gao and doctor Xiaolin Wang for providing laboratory equipment in the Department of Pharmacology, Shanghai Jiaotong University School of Medicine, and all the clinical embryologists who helped with the collection of follicular fluid in the Shanghai Ninth People’s Hospital. We would like to thank not only the doctors and nurses, but also our patients and their families who assisted with recruitment for this study.</p></ack><fn-group><fn id="fn8-medscimonit-24-3357" fn-type="COI-statement"><p><bold>Cooflicts of interests</bold></p><p>None.</p></fn><fn id="fn9-medscimonit-24-3357"><p><bold>Source of support:</bold> This work was supported by grants from the Science and Technology Commission of Shanghai Municipality (No. 15411953000, 15411964500, and 14411964300); the National Natural Science Foundation of China (No.81571397); and the Merck Serono Reproductive Medicine fund</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-24-3357"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>JY</given-names></name><etal></etal></person-group><article-title>Preliminary proteomic analysis on the alterations in follicular fluid proteins from women undergoing natural cycles or controlled ovarian hyperstimulation</article-title><source>J Assist Reprod Genet</source><year>2015</year><volume>32</volume><fpage>417</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">25595538</pub-id></element-citation></ref><ref id="b2-medscimonit-24-3357"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macklon</surname><given-names>NS</given-names></name><name><surname>Stouffer</surname><given-names>RL</given-names></name><name><surname>Giudice</surname><given-names>LC</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name></person-group><article-title>The science behind 25 years of ovarian stimulation for <italic>in vitro</italic> fertilization</article-title><source>Endocr Rev</source><year>2006</year><volume>27</volume><fpage>170</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">16434510</pub-id></element-citation></ref><ref id="b3-medscimonit-24-3357"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>MH</given-names></name><name><surname>Cha</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>CW</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><etal></etal></person-group><article-title>The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in <italic>in vitro</italic></article-title><source>Clin Exp Reprod Med</source><year>2013</year><volume>40</volume><fpage>90</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">23875165</pub-id></element-citation></ref><ref id="b4-medscimonit-24-3357"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayot</surname><given-names>D</given-names></name><name><surname>Klachook</surname><given-names>S</given-names></name><name><surname>Casper</surname><given-names>RF</given-names></name></person-group><article-title>Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: A prospective pilot study</article-title><source>Reprod Biol Endocrinol</source><year>2013</year><volume>11</volume><fpage>95</fpage><lpage>97</lpage></element-citation></ref><ref id="b5-medscimonit-24-3357"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sills</surname><given-names>ES</given-names></name><name><surname>Collins</surname><given-names>GS</given-names></name><name><surname>Salem</surname><given-names>SA</given-names></name><name><surname>Jones</surname><given-names>CA</given-names></name><etal></etal></person-group><article-title>Balancing selected medication costs with total number of daily injections: A preference analysis of GnRH-agonist and antagonist protocols by IVF patients</article-title><source>Reprod Biol Endocrinol</source><year>2012</year><volume>10</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22252173</pub-id></element-citation></ref><ref id="b6-medscimonit-24-3357"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mourad</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Farquhar</surname><given-names>C</given-names></name></person-group><article-title>Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews</article-title><source>Cochrane Database Syst Rev</source><year>2017</year><volume>1</volume><fpage>2</fpage><lpage>10</lpage></element-citation></ref><ref id="b7-medscimonit-24-3357"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichman</surname><given-names>DE</given-names></name><name><surname>Zakarin</surname><given-names>L</given-names></name><name><surname>Chao</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in <italic>in vitro</italic> fertilization cycles</article-title><source>Fertil Steril</source><year>2014</year><volume>102</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">24882557</pub-id></element-citation></ref><ref id="b8-medscimonit-24-3357"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Hong</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Luteal-phase ovarian stimulation case report: Three-year follow-up of a twin birth</article-title><source>J IVF Reprod Med Genet</source><year>2013</year><volume>1</volume><fpage>106</fpage></element-citation></ref><ref id="b9-medscimonit-24-3357"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Hong</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing IVF/ICSI treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles</article-title><source>Fertil Steril</source><year>2014</year><volume>101</volume><fpage>105</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">24161646</pub-id></element-citation></ref><ref id="b10-medscimonit-24-3357"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing contolled ovatian hyperstimulation for <italic>in vitro</italic> fetilization</article-title><source>Fertil Steril</source><year>2015</year><volume>104</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">25956370</pub-id></element-citation></ref><ref id="b11-medscimonit-24-3357"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massin</surname><given-names>N</given-names></name></person-group><article-title>New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF</article-title><source>Hum Reprod Update</source><year>2017</year><volume>23</volume><fpage>211</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">28062551</pub-id></element-citation></ref><ref id="b12-medscimonit-24-3357"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>M</given-names></name><name><surname>Cottell</surname><given-names>E</given-names></name><name><surname>Gibney</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>An investigation into the relationship between the metabolic profile of follicular fluid, oocyte developmental potential, and implantation outcome</article-title><source>Fertil Steril</source><year>2012</year><volume>97</volume><fpage>1078</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">22365382</pub-id></element-citation></ref><ref id="b13-medscimonit-24-3357"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambekar</surname><given-names>AS</given-names></name><name><surname>Kelkar</surname><given-names>DS</given-names></name><name><surname>Pinto</surname><given-names>SM</given-names></name><etal></etal></person-group><article-title>Proteomics of follicular fluid from women with polycystic ovary syndrome suggests molecular defects in follicular development</article-title><source>J Clin Endocrinol Metab</source><year>2015</year><volume>100</volume><fpage>744</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">25393639</pub-id></element-citation></ref><ref id="b14-medscimonit-24-3357"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: A double-blind randomized crossover clinical trial</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><fpage>29</fpage><lpage>39</lpage></element-citation></ref><ref id="b15-medscimonit-24-3357"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Luteal-phase ovarian stimulation <italic>vs</italic>. conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: A large retrospective cohort study</article-title><source>Clin Endocrinol</source><year>2016</year><volume>84</volume><fpage>720</fpage><lpage>28</lpage></element-citation></ref><ref id="b16-medscimonit-24-3357"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavilla</surname><given-names>MV</given-names></name><name><surname>Bianchi</surname><given-names>CP</given-names></name><name><surname>Aguilera</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Hormonal changes and follicular activity after treatment with intravaginal progesterone-releasing devices in llamas</article-title><source>Reprod Dom Anim</source><year>2016</year><volume>51</volume><fpage>1</fpage><lpage>10</lpage></element-citation></ref><ref id="b17-medscimonit-24-3357"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>GP</given-names></name><name><surname>Matteri</surname><given-names>RL</given-names></name><name><surname>Kastelic</surname><given-names>JP</given-names></name><etal></etal></person-group><article-title>Association between surges of follicle-stimulating hormone and the emergence of follicular waves in heifers</article-title><source>J Reprod Fertil</source><year>1992</year><volume>94</volume><fpage>177</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">1552480</pub-id></element-citation></ref><ref id="b18-medscimonit-24-3357"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venetis</surname><given-names>CA</given-names></name><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Bosdou</surname><given-names>JK</given-names></name><etal></etal></person-group><article-title>Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles</article-title><source>Hum Reprod</source><year>2016</year><volume>31</volume><fpage>1859</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">27301360</pub-id></element-citation></ref><ref id="b19-medscimonit-24-3357"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soules</surname><given-names>MR</given-names></name><name><surname>Steiner</surname><given-names>RA</given-names></name><name><surname>Clifton</surname><given-names>DK</given-names></name><etal></etal></person-group><article-title>Progesterone modulation of pulsatile luteinizing hormone secretion in normal women</article-title><source>J Clin Endocrinol Metab</source><year>1984</year><volume>58</volume><fpage>378</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">6420438</pub-id></element-citation></ref><ref id="b20-medscimonit-24-3357"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letterie</surname><given-names>GS</given-names></name></person-group><article-title>Inhibition of gonadotropin surge by a brief midcycle regimen of ethinyl estradiol andnorethindrone: possible role in <italic>in vitro</italic> fertilization</article-title><source>Gynecol Endocrinol</source><year>2000</year><volume>14</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">10813099</pub-id></element-citation></ref><ref id="b21-medscimonit-24-3357"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chai</surname><given-names>WR</given-names></name><etal></etal></person-group><article-title>The pregnancy outcome of progesterone-primed ovarian stimulation using medroxyprogesterone acetate 4mg versus 10mg daily in infertile women undergoing <italic>in vitro</italic> fertilization: A randomized controlled trial</article-title><source>BJOG</source><year>2017</year><volume>9</volume><fpage>1471</fpage><lpage>0528</lpage></element-citation></ref><ref id="b22-medscimonit-24-3357"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breen</surname><given-names>SM</given-names></name><name><surname>Knox</surname><given-names>RV</given-names></name></person-group><article-title>The impact of dose of FSH (Folltropin) containing LH (Lutropin) on follicular development, estrus and ovulation responses in prepubertal gilts</article-title><source>Anim Reprod Sci</source><year>2012</year><volume>132</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">22683028</pub-id></element-citation></ref><ref id="b23-medscimonit-24-3357"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamb</surname><given-names>JD</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>McCulloch</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in <italic>in vitro</italic> fertilization cycles: A randomized, double-blind, placebo-controlled trial</article-title><source>Fertil Steril</source><year>2011</year><volume>95</volume><fpage>1655</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">21315341</pub-id></element-citation></ref><ref id="b24-medscimonit-24-3357"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>I</given-names></name><name><surname>Pla</surname><given-names>M</given-names></name><name><surname>Vicente</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Induction of ovulation in rabbits with pure urinary luteinizing hormone and human chorionic gonadotrophin: comparison of oocyte and embryo quality</article-title><source>Hum Reprod</source><year>1991</year><volume>6</volume><fpage>1449</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">1770143</pub-id></element-citation></ref><ref id="b25-medscimonit-24-3357"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannock</surname><given-names>DA</given-names></name><name><surname>Lewis</surname><given-names>RN</given-names></name><name><surname>McMullen</surname><given-names>TP</given-names></name><name><surname>McElhaney</surname><given-names>RN</given-names></name></person-group><article-title>The effect of variations in phospholipid and sterol structure on the nature of lipidsterol interactions in lipid bilayer model membranes</article-title><source>Chem Phys Lipids</source><year>2010</year><volume>163</volume><fpage>403</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">20371224</pub-id></element-citation></ref><ref id="b26-medscimonit-24-3357"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Fujimori</surname><given-names>C</given-names></name><name><surname>Hagiwara</surname><given-names>A</given-names></name><name><surname>Ogiwara</surname><given-names>K</given-names></name></person-group><article-title>Recent advances in the understanding of teleost medaka ovulation: The roles of proteases and prostaglandins</article-title><source>Zoolog Sci</source><year>2013</year><volume>30</volume><fpage>239</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">23537233</pub-id></element-citation></ref><ref id="b27-medscimonit-24-3357"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lean</surname><given-names>IJ</given-names></name><name><surname>Porter</surname><given-names>JA</given-names></name><name><surname>Rabiee</surname><given-names>AR</given-names></name><etal></etal></person-group><article-title>Comparison of effects of GnRH and prostaglandin in combination, and prostaglandin on conception rates and time to conception in dairy cows</article-title><source>Aust Vet J</source><year>2003</year><volume>81</volume><fpage>488</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15086085</pub-id></element-citation></ref><ref id="b28-medscimonit-24-3357"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamba</surname><given-names>S</given-names></name><name><surname>Yodoi</surname><given-names>R</given-names></name><name><surname>Segi-Nishida</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Timely interaction between prostaglandin and chemokine signaling is a prerequisite for successful fertilization</article-title><source>Proc Natl Acad Sci USA</source><year>2008</year><volume>105</volume><fpage>14539</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">18794532</pub-id></element-citation></ref><ref id="b29-medscimonit-24-3357"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>D</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name></person-group><article-title>A diet rich in n-3 polyunsaturated fatty acids reduced prostaglandin biosynthesis, ovulation rate, and litter size in mice</article-title><source>Theriogenology</source><year>2012</year><volume>78</volume><fpage>28</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">22460154</pub-id></element-citation></ref><ref id="b30-medscimonit-24-3357"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narumiya</surname><given-names>S</given-names></name><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Ushikubi</surname><given-names>F</given-names></name></person-group><article-title>Prostanoid receptors: Structures, properties and functions</article-title><source>Physiol Rev</source><year>1999</year><volume>79</volume><fpage>1193</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">10508233</pub-id></element-citation></ref><ref id="b31-medscimonit-24-3357"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>YM</given-names></name><name><surname>Zhang</surname><given-names>CQ</given-names></name><name><surname>Lin</surname><given-names>XH</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name></person-group><article-title>Prostaglandin involvement infollicle-stimulating hormone-induced proliferation of granulosa cells from chicken prehierarchical follicles</article-title><source>Prostaglandins Other Lipid Mediat</source><year>2006</year><volume>81</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16997131</pub-id></element-citation></ref><ref id="b32-medscimonit-24-3357"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>SE</given-names></name><name><surname>Friedrich</surname><given-names>MG</given-names></name><name><surname>Mitchell</surname><given-names>TW</given-names></name><etal></etal></person-group><article-title>Human prefrontal cortex phospholipids containing docosahexaenoic acid increase during normal adult aging, whereas those containingarachidonic acid decrease</article-title><source>Neurobiol Aging</source><year>2015</year><volume>36</volume><fpage>1659</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">25676385</pub-id></element-citation></ref><ref id="b33-medscimonit-24-3357"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>G</given-names></name><name><surname>Staron</surname><given-names>MM</given-names></name><name><surname>Gray</surname><given-names>SM</given-names></name><etal></etal></person-group><article-title>IL-7-induced glycerol transport and TAG synthesis promotes memory CD8+ T cell longevity</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>750</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">25957683</pub-id></element-citation></ref><ref id="b34-medscimonit-24-3357"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattaini</surname><given-names>KR</given-names></name><name><surname>Brignole</surname><given-names>EJ</given-names></name><name><surname>Kini</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>An epitope tag alters phosphoglycerate dehydrogenase structure and impairs ability to support cell proliferation</article-title><source>Cancer Metab</source><year>2015</year><volume>3</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">25635223</pub-id></element-citation></ref><ref id="b35-medscimonit-24-3357"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>EM</given-names></name><name><surname>Leese</surname><given-names>HJ</given-names></name></person-group><article-title>A potential role for triglyceride as an energy source during bovine oocyte maturation and early embryo development</article-title><source>Mol Reprod Dev</source><year>2006</year><volume>73</volume><fpage>1195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">16804881</pub-id></element-citation></ref><ref id="b36-medscimonit-24-3357"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Rosas-Oliveira</surname><given-names>R</given-names></name><name><surname>Saraiva</surname><given-names>FB</given-names></name><etal></etal></person-group><article-title>Lipid accumulation and utilization by oocytes and eggs of <italic>Rhodnius prolixus</italic></article-title><source>Arch Insect Biochem Physiol</source><year>2011</year><volume>77</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">21308762</pub-id></element-citation></ref><ref id="b37-medscimonit-24-3357"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrill</surname><given-names>GA</given-names></name><name><surname>Ma</surname><given-names>GY</given-names></name><name><surname>Kostellow</surname><given-names>AB</given-names></name></person-group><article-title>Progesterone-induced phospholipid N-methylation and sphingomyelin synthesis in the amphibian oocyte plasma membrane: A second source of the 1,2-diacylglycerol second messenger associated with the G2/M transition</article-title><source>Biochim Biophys Acta</source><year>1994</year><volume>1224</volume><fpage>589</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">7803520</pub-id></element-citation></ref><ref id="b38-medscimonit-24-3357"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckberg</surname><given-names>WR</given-names></name><name><surname>Szuts</surname><given-names>EZ</given-names></name></person-group><article-title>Diacylglycerol content of <italic>Chaetopterus</italic> oocytes during maturation and fertilization</article-title><source>Dev Biol</source><year>1993</year><volume>159</volume><fpage>732</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">8405692</pub-id></element-citation></ref><ref id="b39-medscimonit-24-3357"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albessard</surname><given-names>E</given-names></name><name><surname>Mayzaud</surname><given-names>P</given-names></name><name><surname>Cuzin-Roudy</surname><given-names>J</given-names></name></person-group><article-title>Variation of lipid classes among organs of the Northern krill <italic>Meganyctiphanes norvegica</italic>, with respect to reproduction</article-title><source>Comp Biochem Physiol A Mol Integr Physiol</source><year>2001</year><volume>129</volume><fpage>373</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">11423310</pub-id></element-citation></ref><ref id="b40-medscimonit-24-3357"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drissner</surname><given-names>D</given-names></name><name><surname>Kunze</surname><given-names>G</given-names></name><name><surname>Callewaert</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Lyso-phosphatidylcholine is a signal in the arbuscular mycorrhizal symbiosis</article-title><source>Science</source><year>2007</year><volume>318</volume><fpage>265</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17932296</pub-id></element-citation></ref><ref id="b41-medscimonit-24-3357"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriraman</surname><given-names>V</given-names></name><name><surname>Modi</surname><given-names>SR</given-names></name><name><surname>Bodenburg</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Identification of ERK and JNK as signaling mediators on protein kinase C activation in cultured granulosa cells</article-title><source>Endocrinol</source><year>2008</year><volume>294</volume><fpage>52</fpage><lpage>60</lpage></element-citation></ref><ref id="b42-medscimonit-24-3357"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>F</given-names></name><name><surname>Corcini</surname><given-names>CD</given-names></name><name><surname>Mondadori</surname><given-names>RG</given-names></name><etal></etal></person-group><article-title>Leptin and mitogen-activated protein kinase (MAPK) in oocytes of sows and gilts</article-title><source>Anim Reprod Sci</source><year>2013</year><volume>139</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">23602489</pub-id></element-citation></ref><ref id="b43-medscimonit-24-3357"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokumura</surname><given-names>A</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>Nishioka</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of <italic>in vitro</italic> fertilization patients</article-title><source>Biol Reprod</source><year>1999</year><volume>61</volume><fpage>195</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">10377049</pub-id></element-citation></ref><ref id="b44-medscimonit-24-3357"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckingham</surname><given-names>KL</given-names></name><name><surname>Stone</surname><given-names>PR</given-names></name><name><surname>Smith</surname><given-names>JF</given-names></name><name><surname>Chamley</surname><given-names>LW</given-names></name></person-group><article-title>Antiphospholipid antibodies in serum and follicular fluid-is there a correlation with IVF implantation failure?</article-title><source>Hum Reprod</source><year>2006</year><volume>21</volume><fpage>728</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">16253967</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-24-3357" position="float"><label>Figure 1</label><caption><p>The trends of serum hormones during ovarian stimulation in the PPOS and short-term protocols. E2 – estrogen; FSH – follicle-stimulating hormone; LH – luteinizing hormone; P – progesterone; PPOS – progestin-primed ovarian stimulation; MC3 – menstrual cycle day 3; MC10–12 – menstrual cycle day 10–12; (<bold>A</bold>) FSH (IU/L); (<bold>B</bold>) LH (IU/L); (<bold>C</bold>) E2 (ngl/L); (<bold>D</bold>). P (ng/L); n=6; * represent short-term protocol and PPOS protocols, and P&lt;0.05.</p></caption><graphic xlink:href="medscimonit-24-3357-g001"></graphic></fig><fig id="f2-medscimonit-24-3357" position="float"><label>Figure 2</label><caption><p>Score plot of OPLS-DA analysis. OPLS-DA – orthogonal partial least square-discriminate analysis; PPOS – progestin-primed ovarian stimulation; A – Short-term protocol, B – PPOS (4 mg) protocol, C – PPOS (10 mg) protocol.</p></caption><graphic xlink:href="medscimonit-24-3357-g002"></graphic></fig><fig id="f3-medscimonit-24-3357" position="float"><label>Figure 3</label><caption><p>Differences in metabolite levels among 3 groups. DAG – diacylglycerol; LPC – lysophosphatidylcholine; LPE – lysophosphatidylethanolamine; LPI – lysophosphatidylinositol; PE – phosphatidylethanolamine; PG – phosphatidylglycerol; TAG – triacylglycerol; PPOS – progestin-primed ovarian stimulation; A – Short-term protocol, B – PPOS (4 mg) protocol, C – PPOS (10 mg) protocol.</p></caption><graphic xlink:href="medscimonit-24-3357-g003"></graphic></fig><fig id="f4-medscimonit-24-3357" position="float"><label>Figure 4</label><caption><p>Differentially expressed lipids in PPOS protocol. DAG – diacylglycerol; LPC – lysophosphatidylcholine; LPE – lysophosphatidylethanolamine; LPI – lysophosphatidylinositol; PE – phosphatidylethanolamine; PG – phosphatidylglycerol; TAG – triacylglycerol; PPOS – progestin-primed ovarian stimulation; (<bold>A</bold>) Heatmap of expression profiles for the 12 lipids that showed significant expression changes, green through red color indicates low to high expression level; A – short-term protocol, B – PPOS (4 mg) protocol, C – PPOS (10 mg) protocol; (<bold>B</bold>) Metabolite-associated correlation analysis, the highest correlation is 1 for the complete positive correlation, the correlation is a minimum of –1 for a complete negative correlation, and the blanks were statistically correlated with a P&gt;0.05 and a color-coded portion of P&lt;0.05.</p></caption><graphic xlink:href="medscimonit-24-3357-g004"></graphic></fig><table-wrap id="t1-medscimonit-24-3357" position="float"><label>Table 1</label><caption><p>Clinical characteristics of the patients included in the study.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Parameter</th><th valign="middle" align="center" rowspan="1" colspan="1">Short-term<break></break>n=31</th><th valign="middle" align="center" rowspan="1" colspan="1">PPOS (4 mg)<break></break>n=28</th><th valign="middle" align="center" rowspan="1" colspan="1">PPOS (10 mg)<break></break>n=34</th><th valign="middle" align="center" rowspan="1" colspan="1">P-value 1</th><th valign="middle" align="center" rowspan="1" colspan="1">P-value 2</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Age</td><td valign="middle" align="center" rowspan="1" colspan="1">31.9±2.8</td><td valign="middle" align="center" rowspan="1" colspan="1">30.7±3.1</td><td valign="middle" align="center" rowspan="1" colspan="1">31.2±2.9</td><td valign="middle" align="center" rowspan="1" colspan="1">.298</td><td valign="middle" align="center" rowspan="1" colspan="1">.592</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Infertility time</td><td valign="middle" align="center" rowspan="1" colspan="1">2.9±3.8</td><td valign="middle" align="center" rowspan="1" colspan="1">2.2±1.3</td><td valign="middle" align="center" rowspan="1" colspan="1">2.7±2.0</td><td valign="middle" align="center" rowspan="1" colspan="1">.109</td><td valign="middle" align="center" rowspan="1" colspan="1">.252</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Basal FSH (IU/ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">5.7±2.3</td><td valign="middle" align="center" rowspan="1" colspan="1">5.7±1.0</td><td valign="middle" align="center" rowspan="1" colspan="1">5.4±1.2</td><td valign="middle" align="center" rowspan="1" colspan="1">.961</td><td valign="middle" align="center" rowspan="1" colspan="1">.840</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Basal LH (IU/ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">3.3±1.4</td><td valign="middle" align="center" rowspan="1" colspan="1">3.5±1.2</td><td valign="middle" align="center" rowspan="1" colspan="1">3.8±1.0</td><td valign="middle" align="center" rowspan="1" colspan="1">.836</td><td valign="middle" align="center" rowspan="1" colspan="1">.113</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Basal E2 (pg/ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">27.3±20.5</td><td valign="middle" align="center" rowspan="1" colspan="1">28.8±20.0</td><td valign="middle" align="center" rowspan="1" colspan="1">25.5±16.7</td><td valign="middle" align="center" rowspan="1" colspan="1">.810</td><td valign="middle" align="center" rowspan="1" colspan="1">.738</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Basal P (ng/ml)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.4±1.0</td><td valign="middle" align="center" rowspan="1" colspan="1">0.3±0.1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.3±0.2</td><td valign="middle" align="center" rowspan="1" colspan="1">.920</td><td valign="middle" align="center" rowspan="1" colspan="1">.487</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">AFC (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">10.1±3.3</td><td valign="middle" align="center" rowspan="1" colspan="1">9.9±2.6</td><td valign="middle" align="center" rowspan="1" colspan="1">11.8±4.1</td><td valign="middle" align="center" rowspan="1" colspan="1">.673</td><td valign="middle" align="center" rowspan="1" colspan="1">.116</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Primary infertility (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">54.1</td><td valign="middle" align="center" rowspan="1" colspan="1">52.4</td><td valign="middle" align="center" rowspan="1" colspan="1">53.8</td><td valign="middle" align="center" rowspan="1" colspan="1">0.133</td><td valign="middle" align="center" rowspan="1" colspan="1">0.106</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Previous IVF attempts (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">0.9±1.4</td><td valign="middle" align="center" rowspan="1" colspan="1">1.0±1.1</td><td valign="middle" align="center" rowspan="1" colspan="1">0.9±1.5</td><td valign="middle" align="center" rowspan="1" colspan="1">0.929</td><td valign="middle" align="center" rowspan="1" colspan="1">0.966</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="middle" align="center" rowspan="1" colspan="1">21.7±3.7</td><td valign="middle" align="center" rowspan="1" colspan="1">21.7±2.4</td><td valign="middle" align="center" rowspan="1" colspan="1">21.4±1.9</td><td valign="middle" align="center" rowspan="1" colspan="1">.988</td><td valign="middle" align="center" rowspan="1" colspan="1">.680</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Total dose of hMG (IU)</td><td valign="middle" align="center" rowspan="1" colspan="1">1702±138</td><td valign="middle" align="center" rowspan="1" colspan="1">1913±147</td><td valign="middle" align="center" rowspan="1" colspan="1">1894±345</td><td valign="middle" align="center" rowspan="1" colspan="1">.149</td><td valign="middle" align="center" rowspan="1" colspan="1">.372</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Total dose of hCG (IU)</td><td valign="middle" align="center" rowspan="1" colspan="1">2067±13099</td><td valign="middle" align="center" rowspan="1" colspan="1">2250±1357</td><td valign="middle" align="center" rowspan="1" colspan="1">2150±1182</td><td valign="middle" align="center" rowspan="1" colspan="1">.878</td><td valign="middle" align="center" rowspan="1" colspan="1">.809</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Total dose of MPA (mg)</td><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="center" rowspan="1" colspan="1">36.3±5.0</td><td valign="middle" align="center" rowspan="1" colspan="1">90.0±12.9</td><td valign="middle" align="center" rowspan="1" colspan="1">.000<xref ref-type="table-fn" rid="tfn2-medscimonit-24-3357">*</xref></td><td valign="middle" align="center" rowspan="1" colspan="1">.000<xref ref-type="table-fn" rid="tfn2-medscimonit-24-3357">*</xref></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Ocytes retrieved (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">11.5±9.9</td><td valign="middle" align="center" rowspan="1" colspan="1">14.1±13.8</td><td valign="middle" align="center" rowspan="1" colspan="1">14.6±26.1</td><td valign="middle" align="center" rowspan="1" colspan="1">.143</td><td valign="middle" align="center" rowspan="1" colspan="1">.473</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">MII oocytes (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">9.2±0.9</td><td valign="middle" align="center" rowspan="1" colspan="1">10.8±0.7</td><td valign="middle" align="center" rowspan="1" colspan="1">10.9±0.4</td><td valign="middle" align="center" rowspan="1" colspan="1">.980</td><td valign="middle" align="center" rowspan="1" colspan="1">.847</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Fertilization (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">7.7±0.6</td><td valign="middle" align="center" rowspan="1" colspan="1">8.7±0.7</td><td valign="middle" align="center" rowspan="1" colspan="1">8.8±0.5</td><td valign="middle" align="center" rowspan="1" colspan="1">.066</td><td valign="middle" align="center" rowspan="1" colspan="1">.078</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Clevage (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">7.6±0.6</td><td valign="middle" align="center" rowspan="1" colspan="1">8.7±0.7</td><td valign="middle" align="center" rowspan="1" colspan="1">8.8±0.5</td><td valign="middle" align="center" rowspan="1" colspan="1">.066</td><td valign="middle" align="center" rowspan="1" colspan="1">.078</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">High-quality embryos</td><td valign="middle" align="center" rowspan="1" colspan="1">3.2±2.6</td><td valign="middle" align="center" rowspan="1" colspan="1">3.9±2.6</td><td valign="middle" align="center" rowspan="1" colspan="1">4.0±3.4</td><td valign="middle" align="center" rowspan="1" colspan="1">.516</td><td valign="middle" align="center" rowspan="1" colspan="1">.366</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">All cryopreserved embryos (n)</td><td valign="middle" align="center" rowspan="1" colspan="1">3.2±2.5</td><td valign="middle" align="center" rowspan="1" colspan="1">3.9±2.5</td><td valign="middle" align="center" rowspan="1" colspan="1">4.0±3.3</td><td valign="middle" align="center" rowspan="1" colspan="1">.523</td><td valign="middle" align="center" rowspan="1" colspan="1">.368</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Biochemical pregnancy rate per transfer (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">48 (15/31)</td><td valign="middle" align="center" rowspan="1" colspan="1">57 (16/28)</td><td valign="middle" align="center" rowspan="1" colspan="1">58 (20/34)</td><td valign="middle" align="center" rowspan="1" colspan="1">.217</td><td valign="middle" align="center" rowspan="1" colspan="1">.164</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Clinical pregnancy rate (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">42 (13/31)</td><td valign="middle" align="center" rowspan="1" colspan="1">50 (14/28)</td><td valign="middle" align="center" rowspan="1" colspan="1">50 (17/34)</td><td valign="middle" align="center" rowspan="1" colspan="1">.242</td><td valign="middle" align="center" rowspan="1" colspan="1">.205</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Birth weight (g)</td><td valign="middle" align="center" rowspan="1" colspan="1">2998±223</td><td valign="middle" align="center" rowspan="1" colspan="1">3164±634</td><td valign="middle" align="center" rowspan="1" colspan="1">3116±755</td><td valign="middle" align="center" rowspan="1" colspan="1">.245</td><td valign="middle" align="center" rowspan="1" colspan="1">.432</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-24-3357"><p>Plus–minus values represent the mean ±SD. The categorical datas were analysed by Chi-square. The baseline hormonal profile was typically assayed in patients treated with on menstrual days 2–4. P-value 1 for the comparison between short-term <italic>vs.</italic> PPOS (4 mg), P-value 2 for the comparison between short-term <italic>vs.</italic> PPOS (10 mg). AFC – antral follicles; BMI – body mass index; E2 – estrogen; FSH – follicle-stimulating hormone; hCG – human chorionic gonadotropin; hMG – human menopausal gonadotropin; LH – luteinizing hormone; MC – mentrual cycle day 3; MPA – medroxyprogesterone 17-acetate; P – progesterone; PPOS – progestin primed ovarian stimulation;</p></fn><fn id="tfn2-medscimonit-24-3357"><label>*</label><p>represent a statistically significant difference (P&lt;0.05).</p></fn></table-wrap-foot></table-wrap></floats-group></article>